» Articles » PMID: 18925631

Differentiation Therapy of Hepatocellular Carcinoma in Mice with Recombinant Adenovirus Carrying Hepatocyte Nuclear Factor-4alpha Gene

Overview
Journal Hepatology
Specialty Gastroenterology
Date 2008 Oct 18
PMID 18925631
Citations 91
Authors
Affiliations
Soon will be listed here.
Abstract

Unlabelled: Previous studies have shown that hepatocyte nuclear factor-4alpha (HNF4alpha) is a central regulator of differentiated hepatocyte phenotype and forced expression of HNF4alpha could promote reversion of tumors toward a less invasive phenotype. However, the effect of HNF4alpha on cancer stem cells (CSCs) and the treatment of hepatocellular carcinoma (HCC) with HNF4alpha have not been reported. In this study, an adenovirus-mediated gene delivery system, which could efficiently transfer and express HNF4alpha, was generated to determine its effect on hepatoma cells (Hep3B and HepG2) in vitro and investigate the anti-tumor effect of HNF4alpha in mice. Our results demonstrated that forced re-expression of HNF4alpha induced the differentiation of hepatoma cells into hepatocytes, dramatically decreased "stemness" gene expression and the percentage of CD133(+) and CD90(+) cells, which are considered as cancer stem cells in HCC. Meanwhile, HNF4alpha reduced cell viability through inducing apparent apoptosis in Hep3B, while it induced cell cycle arrest and cellular senescence in HepG2. Moreover, infection of hepatoma cells by HNF4alpha abolished their tumorigenesis in mice. Most interestingly, systemic administration of adenovirus carrying the HNF4alpha gene protected mice from liver metastatic tumor formation, and intratumoral injection of HNF4alpha also displayed significant antitumor effects on transplanted tumor models.

Conclusion: The striking suppression effect of HNF4alpha on tumorigenesis and tumor development is attained by inducing the differentiation of hepatoma cells--especially CSCs--into mature hepatocytes, suggesting that differentiation therapy with HNF4alpha may be an effective treatment for HCC patients. Our study also implies that differentiation therapy may present as one of the best strategies for cancer treatment through the induction of cell differentiation by key transcription factors.

Citing Articles

SOX9 Overexpression Ameliorates Metabolic Dysfunction-associated Steatohepatitis Through Activation of the AMPK Pathway.

Deng J, Ding K, Liu S, Chen F, Huang R, Xu B J Clin Transl Hepatol. 2025; 13(3):189-199.

PMID: 40078197 PMC: 11894392. DOI: 10.14218/JCTH.2024.00197.


HNF4α inhibits the malignancy of intrahepatic cholangiocarcinoma by suppressing the Wnt signaling pathway.

Xu B, Ding C, Liu Y, Luo Y, Deng J, Liu S Transl Oncol. 2025; 53:102290.

PMID: 39864343 PMC: 11802383. DOI: 10.1016/j.tranon.2025.102290.


Cell-permeated peptide P-T3H2 inhibits malignancy on hepatocellular carcinoma through stabilizing HNF4α protein.

Wu S, Xiao M, Liu F, Hong H, Ding C, Zhang X Discov Oncol. 2024; 15(1):752.

PMID: 39638897 PMC: 11621286. DOI: 10.1007/s12672-024-01661-2.


FGL1 and FGL2: emerging regulators of liver health and disease.

Chen J, Wu L, Li Y Biomark Res. 2024; 12(1):53.

PMID: 38816776 PMC: 11141035. DOI: 10.1186/s40364-024-00601-0.


The transcription factor HNF-4α: a key player in haematological disorders.

Belali T, Abomughaid M, Alhujaily M Arch Med Sci. 2023; 19(6):1646-1652.

PMID: 38058729 PMC: 10696958. DOI: 10.5114/aoms/141219.